- Pretest probability first (Wells / clinical gestalt). Low → PERC or age-adjusted D-dimer (age × 10 if >50).
- High probability → CTPA (start anticoagulation while you wait if bleed risk is low).
- Risk-stratify: shock? → high risk → systemic lysis (alteplase 100 mg / 2 h). RV strain + troponin → intermediate-high → monitor, rescue lysis if crash.
- Most patients → DOAC (apixaban 10 mg BID × 7 d → 5 mg BID). Low-risk (sPESI 0) → early discharge.
- Activate the PERT for intermediate-high and high risk.
Pathophysiology in 60 seconds
⌄
- Virchow: stasis + endothelial injury + hypercoagulability → DVT (mostly proximal leg) → embolizes.
- Clot raises pulmonary vascular resistance → RV pressure overload → RV dilates, septum shifts left → LV underfilled → low output → shock.
- RV ischemia (high wall stress + low coronary flow) → troponin up → death spiral.
- Hypoxemia from V/Q mismatch; dead space → high minute ventilation, low PaCO₂.
The RV is a thin-walled sprinter, not a weightlifter. Ask it to push against a sudden clot and it fails fast. That is why RV size on echo predicts outcome.
Diagnosis
⌄
| Wells criteria | Points |
|---|---|
| Clinical signs of DVT | 3 |
| PE most likely diagnosis | 3 |
| HR >100 | 1.5 |
| Immobilization ≥3 d or surgery <4 wk | 1.5 |
| Prior DVT/PE | 1.5 |
| Hemoptysis | 1 |
| Cancer (active) | 1 |
≤4 = PE unlikely → D-dimer. >4 = likely → CTPA.
- PERC (all 8 negative in low gestalt → no testing): age <50, HR <100, SpO₂ ≥95%, no hemoptysis, no estrogen, no prior VTE, no unilateral leg swelling, no recent surgery/trauma.
- YEARS algorithm: 0 items → D-dimer <1000 rules out; ≥1 → <500.
- CTPA contraindicated → V/Q scan (normal CXR) or leg Doppler (positive DVT = treat).
- ECG: sinus tachycardia (most common), S1Q3T3, RV strain, new RBBB.
Risk stratification
⌄
Low risksPESI 0, normal RV
DOAC, early discharge
IntermediateRV strain ± troponin↑
heparin, watch closely
High risk (massive)SBP <90 ≥15 min / shock
systemic lysis or catheter / surgery
| Tool | Low-risk if |
|---|---|
| sPESI | 0 points: age ≤80, no cancer, no chronic cardiopulmonary disease, HR <110, SBP ≥100, SpO₂ ≥90% |
| Hestia | All 11 criteria negative → outpatient |
| RV on CT/echo | RV/LV ratio <1.0 |
| Troponin / BNP | Normal |
Management
⌄
| Drug | Dose |
|---|---|
| Apixaban | 10 mg BID × 7 d → 5 mg BID |
| Rivaroxaban | 15 mg BID × 21 d → 20 mg daily (with food) |
| Enoxaparin | 1 mg/kg SC q12h (→ DOAC or warfarin) |
| UFH | 80 U/kg bolus → 18 U/kg/h — use if lysis/procedure may be needed, CrCl <30, unstable |
| Dabigatran / edoxaban | After ≥5 d of parenteral therapy |
- Cancer-associated VTE: apixaban, rivaroxaban, edoxaban or LMWH (caution GI/GU cancers with bleeding).
- Avoid DOACs: antiphospholipid syndrome (triple positive) → warfarin; pregnancy → LMWH.
- Systemic alteplase 100 mg IV over 2 h (stop heparin during infusion, then restart).
- Cardiac arrest from PE → alteplase 50 mg bolus, continue CPR 60–90 min.
- Contraindicated / failed → catheter-directed therapy or surgical embolectomy; VA-ECMO bridge.
- Avoid big fluid boluses (RV is overloaded); norepinephrine for hypotension; avoid intubation if possible (positive pressure → collapse).
| Situation | Duration |
|---|---|
| Major transient provoker (surgery, trauma) | 3 months |
| Minor/transient (travel, estrogen) | 3 months, consider longer |
| Unprovoked | Extended (indefinite) if bleeding risk acceptable; reduced-dose apixaban 2.5 mg BID after 6 mo is an option |
| Active cancer | While cancer active |
| Recurrent VTE | Indefinite |
- IVC filter only if anticoagulation is contraindicated (remove later).
- Subsegmental, single, no DVT, low risk → surveillance can be discussed.
Pitfalls
⌄
- D-dimer in high-probability patients (a negative does not rule out).
- Withholding anticoagulation while waiting hours for CT in high suspicion.
- Fluids for RV failure shock.
- Thrombophilia testing during the acute event (results unreliable on heparin/acute clot).
Board corner
⌄
| Stem | Answer |
|---|---|
| PE, BP 75/40 | Systemic thrombolysis |
| PE, normal BP, RV dilation + troponin up | Anticoagulate, monitor; rescue lysis if worsens |
| PE + active GI bleed | IVC filter |
| Pregnant, suspected PE | Leg Doppler / CTPA or V/Q; treat with LMWH |
| Unprovoked PE, done 6 months, low bleed risk | Continue (extended) anticoagulation |
| Triple-positive APS | Warfarin, not DOAC |
References
⌄
- Konstantinides SV, et al. 2019 ESC Guidelines for acute PE. Eur Heart J. 2020;41:543.
- Stevens SM, et al. CHEST Guideline: Antithrombotic Therapy for VTE (2nd update). Chest. 2021;160:e545.
- Ortel TL, et al. ASH 2020 guidelines for VTE treatment. Blood Adv. 2020;4:4693.